While Botox may still be the household name for the neuromodulator market, new entries threaten to seize some of its market shares, and for a good reason. RT002 is set to be a game-changer according to preliminary findings during clinical trials.
RT002’s competitors boast results that last approximately 3 months, while RT002 is on track to deliver six months of noticeable results consistently. Once this injectable hits the market, it is expected that patients will receive similar results to other neurotoxins at half the amount of those treatments. Can you imagine? The makers of RT002 did!
This neurotoxin is currently intended for aesthetic and therapeutic use, including glabellar lines and crow’s feet. Approval for medical use, such as treating migraines, is also being sought.
RT002 represents the fifth entry into the neuromodulator market. As such, it shares its roots with Botox. FDA approval for the use of botulinum toxin was granted to Allergan, the creators of Botox, in 2002. While most people are familiar with the aesthetic uses, there are also many medical possibilities identified more recently.
Fast forward to now, Revance Therapeutics, a fairly new biotechnology company from Silicon Valley has arrived. Revance has developed a unique proprietary stabilizing excipient peptide technology that allows them to differentiate their products from others. Pending FDA approval, RT002 is considered to be an investigational product as it is still going through clinical trials. Initial findings have shown promise as a versatile long-lasting treatment for both aesthetic and medical purposes. Exact capabilities will be learned upon the conclusion of trials and being released into the market.
It’s important to know that this injectable is not yet on the market. However, the main benefit of RT002 is in line with similar neurotoxins that help prevent the facial muscles from contracting, thereby minimizing or preventing wrinkles.
Reported benefits specific to RT002 include:
Additional study is needed post-release to determine the full scope of benefits that RT002 will provide in your quest for redefining how aging looks and feels on you.
I’m looking so forward to when RT002 is available as an alternative to Botox and longer lasting!
Finding an expert to help you choose the right neurotoxin currently available is as simple as visiting our online community. At AgeEnvy, valuable information detailing neurotoxin treatments, as well as qualified providers for this treatment, is at your fingertips. Keep in mind that your health and safety comes first with any treatment. That’s why our mission is to give consumers control over their health by getting them connected with providers that are licensed, verified experts focused on cosmetic neurotoxin procedures.
Possible treatment side effects include:
It’s important to remember that common side effects associated with other neurotoxins may be present. At this point, it’s too soon to determine the full range of side effects for RT002.
Here you will find answers to our user’s most common questions. Our goal is to keep you easily informed as you research ways to realize your age management potential. If you have a question that isn’t answered here, please ask a doctor.Find a Provider
RT002 has not hit the market so an exact price range has not been established. Your geographic location along with your chosen practitioner will help determine the final cost. However, the price should be on par with the other options. It is important to note that Jeuveau, which is releasing soon is about 25% cheaper than Botox so it’s reasonable to assume RT002 will be in the middle of these two.
You will need the same amount of initial treatments as with any other neurotoxin. However, the results are anticipated to last longer so the total number will be fewer in the long run.
The treatment is non-invasive and patients have responded well to treatment so recovery time should be minimal if at all. For those who experience side effects, they may want to schedule additional rest time depending on their comfort level.
The results of RT002 are on track to be potentially noticed faster than its competitors. However, until all clinical studies are completed, the data can’t be relied on 100%. At the very least, the results will be on par with the other neurotoxins.
Initial findings during trials have shown that RT002 should provide six months worth of results. Keep in mind that this is subject to change until the findings are complete.
Yes there are. To date, there are four other neurotoxins that all boast similar results available for patient use. They are Botox, Dysport, Xeomin, and Jeuveau. As of right now, RT002 is unavailable.